Literature DB >> 1857001

[Abnormal prothrombin in acute hepatic failure: the characterization and clinical evaluation].

Y Takikawa1.   

Abstract

Abnormal prothrombin was detected by latex agglutination method in the plasma of the patients with acute hepatic failure (AHF) at significantly higher rate (82% of fulminant hepatitis and 100% of subacute hepatitis) than in acute hepatitis (33%). The concentration of abnormal prothrombin was also significantly higher in acute hepatic failure. Since the concentration of abnormal prothrombin reversely correlated with that of hepaplastin test or prothrombin time, the measurement of plasma abnormal prothrombin seemed to be useful in monitoring the severity of acute hepatic injury. Interestingly, enzyme immunoassay which is specific for des-gamma-carboxy prothrombin (PIVKA-II) could not detect abnormal prothrombin in acute hepatic failure. Furthermore, in crossed immune-electrophoresis, the abnormal prothrombin in AHF and that in disseminated intravascular coagulation syndrome showed similar mobility differing from PIVKA-II. These results suggest that abnormal prothrombin can be a useful marker for AHF. Further characterization of the abnormal prothrombin may shed light on the mechanisms of severe coagulopathy in AHF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1857001

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  3 in total

1.  Association Between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study.

Authors:  Liping Wang; Jinzhong Dong; Miao Xu; Li Li; Naibin Yang; Guoqing Qian
Journal:  Front Med (Lausanne)       Date:  2022-05-19

2.  The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.

Authors:  Keun Hee Kang; Ji Hoon Kim; Seong Hee Kang; Beom Jae Lee; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Jong Jae Park; Jae Seon Kim; Young Tae Bak; Kwan Soo Byun
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

3.  Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.

Authors:  Youran Chen; Yanyan Yang; Shanshan Li; Minghao Lin; Xueting Xie; Huifang Shi; Yuchun Jiang; Sijie Zheng; Hui Shao; Naibin Yang; Mingqin Lu
Journal:  Front Public Health       Date:  2022-01-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.